HLA variants and TCR diversity against SARS‐CoV ‐2 in the pre‐COVID ‐19 era
HLA · 2023
DOI: 10.1111/tan.15158 ↗Kurz gefasst
Fachartikel in der Zeitschrift HLA, 2023. Verfasst von Stéphane Buhler und 6 weiteren Autor:innen. Beteiligte Einrichtung: Transplantation Immunology Unit and National Reference Laboratory for Histocompatibility, Department of Diagnostic, Geneva University Hospitals, Gene…. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.
Abstract (Originalsprache)
HLA antigen presentation and T‐cell mediated immunity are critical to control acute viral infection such as COVID‐19 caused by SARS‐CoV‐2. Recent data suggest that both the depth of peptide presentation and the breadth of the T‐cell repertoire are associated with disease outcome. It has also been shown that unexposed subjects can develop strong T‐cell responses against SARS‐CoV‐2 due to heterologous immunity. In this study, we explored the anti‐SARS‐CoV‐2 T‐cell repertoire by analyzing previously published T‐cell receptor (TCR) CDR3β immunosequencing data in a cohort of 116 healthy donors and in the context of immune reconstitution after allogeneic hematopoietic stem cell transplantation in 116 recipients collected during the pre‐COVID‐19 era. For this, 143,310 publicly available SARS‐CoV‐2 specific T‐cell sequences were investigated among the 3.5 million clonotypes in the cohort. We also performed HLA class I peptide binding predictions using the reference proteome of the virus and high resolution genotyping data in these patients. We could demonstrate that individuals are fully equipped at the genetic level to recognize SARS‐CoV‐2. This is evidenced by the 5% median cumulative frequency of clonotypes having their sequence matched to a SARS‐CoV‐2 specific T‐cell. In addition, any combination of HLA class I variants in this cohort is associated with a broad capacity of presenting hundreds of SARS‐CoV‐2 derived peptides. These results could be explained by heterologous immunity and random somatic TCR recombination. We speculate that these observations could explain the efficacy of the specific immune response against SARS‐CoV‐2 in individuals without risk factors of immunodeficiency and infected prior to vaccination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Transplantation Immunology Unit and National Reference Laboratory for Histocompatibility, Department of Diagnostic, Geneva University Hospitals, Geneva, Switzerland.
- CANSEARCH Research Platform for Pediatric Oncology and Hematology, Faculty of Medicine, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland.
- Division of Pediatric Oncology and Hematology, Department of Women, Child and Adolescent, University Geneva Hospitals, Geneva, Switzerland.
ORCID-Profile: Stéphane Buhler, Jean Villard
Förderung
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zitieren
APA
Buhler, S., Sollet, Z. C., Bettens, F., Schäfer, A., Ansari, M., Ferrari-Lacraz, S., & Villard, J. (2023). HLA variants and TCR diversity against SARS‐CoV ‐2 in the pre‐COVID ‐19 era. HLA. https://doi.org/10.1111/tan.15158
Vancouver
Buhler S, Sollet ZC, Bettens F, Schäfer A, Ansari M, Ferrari-Lacraz S, et al. HLA variants and TCR diversity against SARS‐CoV ‐2 in the pre‐COVID ‐19 era. HLA. 2023. doi:10.1111/tan.15158
BibTeX
@article{Buhler2023,
author = {Buhler, Stéphane and Sollet, Zuleika Calderin and Bettens, Florence and Schäfer, Antonia and Ansari, Marc and Ferrari-Lacraz, Sylvie and Villard, Jean},
title = {HLA variants and TCR diversity against SARS‐CoV ‐2 in the pre‐COVID ‐19 era},
journal = {HLA},
year = {2023},
doi = {10.1111/tan.15158}
}
EUVIMED